- Home
- SBLK vs NEO Comparison
SBLK vs NEO Comparison
Compare SBLK & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBLK
- NEO
- Stock Information
- Founded
- SBLK 2006
- NEO 2001
- Country
- SBLK Greece
- NEO United States
- Employees
- SBLK N/A
- NEO N/A
- Industry
- SBLK Marine Transportation
- NEO Precision Instruments
- Sector
- SBLK Consumer Discretionary
- NEO Health Care
- Exchange
- SBLK Nasdaq
- NEO Nasdaq
- Market Cap
- SBLK 1.8B
- NEO 1.2B
- IPO Year
- SBLK N/A
- NEO 1999
- Fundamental
- Price
- SBLK $16.49
- NEO $9.58
- Analyst Decision
- SBLK Strong Buy
- NEO Strong Buy
- Analyst Count
- SBLK 3
- NEO 10
- Target Price
- SBLK $22.67
- NEO $19.78
- AVG Volume (30 Days)
- SBLK 3.0M
- NEO 1.5M
- Earning Date
- SBLK 02-18-2025
- NEO 04-29-2025
- Dividend Yield
- SBLK 12.96%
- NEO N/A
- EPS Growth
- SBLK 60.00
- NEO N/A
- EPS
- SBLK 2.80
- NEO N/A
- Revenue
- SBLK $1,265,458,000.00
- NEO $660,566,000.00
- Revenue This Year
- SBLK N/A
- NEO $12.89
- Revenue Next Year
- SBLK $18.23
- NEO $11.36
- P/E Ratio
- SBLK $5.64
- NEO N/A
- Revenue Growth
- SBLK 33.31
- NEO 11.65
- 52 Week Low
- SBLK $14.30
- NEO $8.98
- 52 Week High
- SBLK $27.47
- NEO $19.11
- Technical
- Relative Strength Index (RSI)
- SBLK 60.15
- NEO 41.35
- Support Level
- SBLK $15.18
- NEO $9.00
- Resistance Level
- SBLK $16.29
- NEO $10.95
- Average True Range (ATR)
- SBLK 0.57
- NEO 0.85
- MACD
- SBLK 0.07
- NEO 0.10
- Stochastic Oscillator
- SBLK 92.82
- NEO 40.98
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.